Jun. 26 at 12:36 PM
$IMUX IMU‑856 update from MedChem Frontiers adds meaningful depth to the story.
First‑in‑class SIRT6 modulator with strong selectivity, drug‑like properties, and clean early safety profile. Oral, non‑immunosuppressive approach with early clinical proof‑of‑concept in celiac disease (improvements in villous structure, biomarkers, nutrient absorption, and symptoms).
Multi‑indication potential beyond celiac (IBD, GI disorders with barrier dysfunction).
No immediate impact on valuation, but important takeaway: IMUX is not just a single‑asset MS company. If Phase 3 data for vidofludimus calcium is positive, IMU‑856 becomes a real source of additional strategic value and partnership optionality.
